We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Read MoreHide Full Article
AstraZeneca plc (AZN - Free Report) presented clinical and safety data from a phase I study (BLOOM) on its lung cancer drug, Tagrisso (osimertinib), in patients with leptomeningeal (LM) disease at the annual meeting of the American Society of Clinical Oncology.
Updated results showed that Tagrisso (160 mg once daily) demonstrated activity through assessments with MRI imaging intracranial response irrespective of the T790M mutation status of patients. Additionally, Tagrisso crossed the blood-brain barrier. The drug resulted in a decline in central nervous system lesions in patients with LM disease in addition to neurological improvement. Moreover, Tagrisso demonstrated a manageable tolerability profile over a treatment period of up to 11 months.
Per the company’s press release, LM disease is a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC), where cancer cells spread to the cerebrospinal fluid. LM disease affects roughly 5% of patients with NSCLC and nearly 9% of those with EGFRm NSCLC.
Considering that the treatment of LM disease is difficult, the safety, tolerability and activity profile that Tagrisso has demonstrated is promising.
We note that Tagrisso (80 mg once daily) gained accelerated approval in Nov 2015 for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It is also approved for the treatment of patients with EGFR T790M mutation-positive locally advanced/metastatic NSCLC in the EU.
Currently, Tagrisso is also being evaluated in the adjuvant setting and in the metastatic first-line setting, including patients with brain metastases, as well as in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
AstraZeneca plc (AZN - Free Report) presented clinical and safety data from a phase I study (BLOOM) on its lung cancer drug, Tagrisso (osimertinib), in patients with leptomeningeal (LM) disease at the annual meeting of the American Society of Clinical Oncology.
Updated results showed that Tagrisso (160 mg once daily) demonstrated activity through assessments with MRI imaging intracranial response irrespective of the T790M mutation status of patients. Additionally, Tagrisso crossed the blood-brain barrier. The drug resulted in a decline in central nervous system lesions in patients with LM disease in addition to neurological improvement. Moreover, Tagrisso demonstrated a manageable tolerability profile over a treatment period of up to 11 months.
Per the company’s press release, LM disease is a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC), where cancer cells spread to the cerebrospinal fluid. LM disease affects roughly 5% of patients with NSCLC and nearly 9% of those with EGFRm NSCLC.
Considering that the treatment of LM disease is difficult, the safety, tolerability and activity profile that Tagrisso has demonstrated is promising.
We note that Tagrisso (80 mg once daily) gained accelerated approval in Nov 2015 for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It is also approved for the treatment of patients with EGFR T790M mutation-positive locally advanced/metastatic NSCLC in the EU.
Currently, Tagrisso is also being evaluated in the adjuvant setting and in the metastatic first-line setting, including patients with brain metastases, as well as in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Bristol-Myers Squibb Company (BMY - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>